Search
Marstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigational[A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.
Droloxifene
go.drugbank.com/drugs/DB15641ExperimentalIts higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.
Categories: Compounds used in a research, industrial, or household settingChlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitAn anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Doxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalIt is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.
Saquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. … [A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Phloxine B
go.drugbank.com/drugs/DB13911ApprovedWithdrawnPhloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing
Categories: Compounds used in a research, industrial, or household settingCysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.
Propoxycaine
go.drugbank.com/drugs/DB09342ApprovedUsed in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592]. … Although no longer available in the United States, this medication was used in combination with procaine to aid in anesthesia during dental procedures [L1592].
ReN001
go.drugbank.com/drugs/DB05236InvestigationalReN001 is a clonal human neural stem cell line developed for clinical use in the treatment of stable disability after stroke. … ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans